PT3572410T - Análogos dioxolano de uridina para o tratamento de cancro - Google Patents

Análogos dioxolano de uridina para o tratamento de cancro

Info

Publication number
PT3572410T
PT3572410T PT191778240T PT19177824T PT3572410T PT 3572410 T PT3572410 T PT 3572410T PT 191778240 T PT191778240 T PT 191778240T PT 19177824 T PT19177824 T PT 19177824T PT 3572410 T PT3572410 T PT 3572410T
Authority
PT
Portugal
Prior art keywords
dioxolan
uridine
analogs
cancer
treatment
Prior art date
Application number
PT191778240T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of PT3572410T publication Critical patent/PT3572410T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT191778240T 2014-08-25 2015-08-24 Análogos dioxolano de uridina para o tratamento de cancro PT3572410T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1450983 2014-08-25
SE1550858 2015-06-22

Publications (1)

Publication Number Publication Date
PT3572410T true PT3572410T (pt) 2022-09-15

Family

ID=54014804

Family Applications (2)

Application Number Title Priority Date Filing Date
PT191778240T PT3572410T (pt) 2014-08-25 2015-08-24 Análogos dioxolano de uridina para o tratamento de cancro
PT157568882T PT3186244T (pt) 2014-08-25 2015-08-24 Análogos dioxolano de uridina para o tratamento de cancro

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT157568882T PT3186244T (pt) 2014-08-25 2015-08-24 Análogos dioxolano de uridina para o tratamento de cancro

Country Status (24)

Country Link
US (7) US10144750B2 (enExample)
EP (2) EP3186244B1 (enExample)
JP (2) JP6663424B2 (enExample)
KR (2) KR102396905B1 (enExample)
CN (4) CN107074826B (enExample)
AU (2) AU2015308988C1 (enExample)
BR (1) BR112017003898B1 (enExample)
CA (2) CA2956251C (enExample)
CY (1) CY1122945T1 (enExample)
DK (2) DK3572410T3 (enExample)
EA (2) EA031106B1 (enExample)
ES (2) ES2927212T3 (enExample)
HR (1) HRP20201023T1 (enExample)
HU (2) HUE059640T2 (enExample)
IL (2) IL250344B (enExample)
MX (1) MX369649B (enExample)
MY (2) MY188089A (enExample)
NZ (2) NZ762628A (enExample)
PH (2) PH12017500184B1 (enExample)
PL (2) PL3186244T3 (enExample)
PT (2) PT3572410T (enExample)
SG (3) SG11201701172SA (enExample)
WO (1) WO2016030335A1 (enExample)
ZA (1) ZA201802864B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3572410T (pt) 2014-08-25 2022-09-15 Medivir Ab Análogos dioxolano de uridina para o tratamento de cancro
CN106543220A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
MX386478B (es) * 2015-12-11 2025-03-18 Laurus Labs Ltd Sintesis diaestereoselectiva de derivados de fosfato y del profarmaco de gemcitabina nuc-1031.
CN109069509B (zh) * 2016-03-02 2020-10-16 麦迪维尔股份公司 索拉非尼或瑞戈非尼与曲沙他滨的氨基磷酸酯前药的组合治疗
CN106432328B (zh) * 2016-09-14 2019-03-22 江苏福瑞生物医药有限公司 一种索非布韦中间体的制备方法
EP3541824A1 (en) * 2016-11-18 2019-09-25 Neurovive Pharmaceutical AB Liver prodrugs of mitochondrial proton ionophores
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
WO2019245444A1 (en) 2018-06-21 2019-12-26 Medivir Ab Base-modified cytidine nucleotides for leukemia therapy
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
CN113453685A (zh) * 2019-02-18 2021-09-28 美迪维尔公司 使用口服给药的二氧戊环核苷酸与抗pd1或抗pdl1单克隆抗体的组合治疗肝癌的方法
CN110964057B (zh) * 2019-12-25 2022-05-06 东南大学 一种利用微流体反应装置制备索非布韦中间体的方法
CN113402546A (zh) * 2020-03-17 2021-09-17 浙江四维医药科技有限公司 一种瑞德西韦磷酸中间体尾链动态动力学拆分方法
TW202200140A (zh) * 2020-04-15 2022-01-01 瑞典商米迪維艾克提伯拉公司 用於肝癌之miv-818/樂伐替尼(lenvatinib)組合療法
CN113754692B (zh) * 2020-06-03 2022-06-10 上海交通大学 瑞德西韦中间体(s,s)-氨基磷酸酯的不对称催化合成方法
CN114685558A (zh) * 2020-12-28 2022-07-01 尚科生物医药（上海）有限公司 一种瑞德西韦中间体的制备方法
CN114249764A (zh) * 2021-11-10 2022-03-29 宁波大学 一种磷酰胺酯类前药的中间体及其制备方法与应用
WO2025155547A1 (en) * 2024-01-17 2025-07-24 University Of Georgia Research Foundation, Inc. An efficient synthesis of beta-l-5-[(e)-2-bromovinyl)-1-((2s,4s)-2-(hydroxymethyl)-1,3-(dioxolane-4-yl) uracil)] (l-bhdu) via chiral pure l-dioxolane

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6022876A (en) 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
CA2425359A1 (en) * 2000-10-13 2002-04-18 Shire Biochem Inc. Dioxolane analogs for improved inter-cellular delivery
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2007106450A2 (en) * 2006-03-10 2007-09-20 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy
CA2662147A1 (en) 2006-09-01 2008-03-13 University Of Georgia Research Foundation, Inc. L-oddc prodrugs for cancer
PL216525B1 (pl) * 2006-10-17 2014-04-30 Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk 5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
AU2014354775A1 (en) * 2013-11-27 2016-05-19 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
PT3572410T (pt) * 2014-08-25 2022-09-15 Medivir Ab Análogos dioxolano de uridina para o tratamento de cancro

Also Published As

Publication number Publication date
US10144750B2 (en) 2018-12-04
CA3128645C (en) 2023-06-27
US20230117570A1 (en) 2023-04-20
ES2796089T3 (es) 2020-11-25
CN110790789B (zh) 2023-05-12
US11447511B2 (en) 2022-09-20
IL250344B (en) 2020-01-30
MY188089A (en) 2021-11-17
NZ729118A (en) 2022-02-25
SG10202001117YA (en) 2020-04-29
US10654877B2 (en) 2020-05-19
AU2015308988A1 (en) 2017-02-23
PH12017500184A1 (en) 2017-06-28
AU2015308988B2 (en) 2018-04-26
EA201890648A3 (ru) 2019-02-28
PL3572410T3 (pl) 2022-10-03
CN110804072A (zh) 2020-02-18
PH12019501919A1 (en) 2020-09-14
EP3572410B1 (en) 2022-07-20
US20200239502A1 (en) 2020-07-30
JP6663424B2 (ja) 2020-03-11
PT3186244T (pt) 2020-05-29
EA201790328A1 (ru) 2017-08-31
HUE050705T2 (hu) 2020-12-28
SG10201911558UA (en) 2020-01-30
NZ762628A (en) 2023-04-28
US10336780B2 (en) 2019-07-02
US20190389890A1 (en) 2019-12-26
IL266766A (en) 2019-07-31
WO2016030335A1 (en) 2016-03-03
EA031106B1 (ru) 2018-11-30
SG11201701172SA (en) 2017-03-30
KR102398714B1 (ko) 2022-05-17
US20190100541A1 (en) 2019-04-04
EA201890648A2 (ru) 2018-08-31
CN110790789A (zh) 2020-02-14
CN110804072B (zh) 2023-05-12
KR20200035482A (ko) 2020-04-03
KR20170046736A (ko) 2017-05-02
MX2017002328A (es) 2017-05-22
MX369649B (es) 2019-11-15
KR102396905B1 (ko) 2022-05-13
US20170267705A1 (en) 2017-09-21
HRP20201023T1 (hr) 2020-10-16
IL250344A0 (en) 2017-03-30
CN111269264A (zh) 2020-06-12
JP2017526677A (ja) 2017-09-14
CA2956251C (en) 2022-10-25
JP6905609B2 (ja) 2021-07-21
AU2015308988C1 (en) 2018-09-06
EA033300B1 (ru) 2019-09-30
JP2020090535A (ja) 2020-06-11
PH12017500184B1 (en) 2017-06-28
US20210054008A1 (en) 2021-02-25
BR112017003898A2 (pt) 2017-12-05
EP3186244A1 (en) 2017-07-05
HUE059640T2 (hu) 2022-12-28
PL3186244T3 (pl) 2020-11-16
DK3186244T3 (da) 2020-07-13
BR112017003898B1 (pt) 2022-10-18
MY198325A (en) 2023-08-24
EP3572410A1 (en) 2019-11-27
AU2018201980A1 (en) 2018-04-12
US10822360B2 (en) 2020-11-03
CY1122945T1 (el) 2021-10-29
US20230382931A1 (en) 2023-11-30
CN107074826B (zh) 2020-05-22
ZA201802864B (en) 2019-07-31
CA3128645A1 (en) 2016-03-03
CN107074826A (zh) 2017-08-18
DK3572410T3 (da) 2022-08-29
AU2018201980B2 (en) 2019-05-16
ES2927212T3 (es) 2022-11-03
CA2956251A1 (en) 2016-03-03
EP3186244B1 (en) 2020-04-22
IL266766B (en) 2020-05-31

Similar Documents

Publication Publication Date Title
IL296080B1 (en) Method for treating cancer
PT3572410T (pt) Análogos dioxolano de uridina para o tratamento de cancro
IL255261A0 (en) Methods for treating cancer
HUE059694T2 (hu) Készítmény rák kezelésére
PL3265053T3 (pl) Sposoby leczenia skóry
PT3283527T (pt) Terapêutica de combinação para o cancro
EP3314027A4 (en) THERAPEUTIC OLIGONUCLEOTIDES
LT3119808T (lt) Antikūnų kompozicijos vėžio gydymui
DK3148529T3 (da) Forbindelser til behandling af hjernecancer
KR20180084772A (ko) 암 치료를 위한 조합 치료법
IL252096A0 (en) Microneedle arrays for cancer therapy applications
BR112016022976A2 (pt) Métodos para o tratamento de hcv
IL256206A (en) Mct4 inhibitors for treating disease
HUE040167T2 (hu) Rákkezelés
DK3393478T3 (da) Kombinationsterapi
HUE056897T2 (hu) Monomaleimid-funkcionalizált platinavegyületek rákterápiához
EP3362091A4 (en) COMBINATION THERAPY
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
DK3329004T3 (da) Terapeutiske oligonukleotider
DK3407909T5 (da) Cancerbehandling
DK3250168T3 (da) Forbedringer vedrørende nethindebehandling
IL258186A (en) Compositions having anti-fugetactic properties for treatment of cancer
UA32276S (uk) Шкіра
TH1601002300A (th) วิถีทางในการสังเคราะห์ 2'-ดีออกซี-2',2'-ไดฟลูออโรเตตระไฮโดรยูริดีน
TH1501007353A (th) สารประกอบชนิดใหม่สำหรับการบำบัดโรคมะเร็ง